- Home
- VERO vs VRAX Comparison
VERO vs VRAX Comparison
Compare VERO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- VRAX
- Stock Information
- Founded
- VERO N/A
- VRAX 2013
- Country
- VERO Canada
- VRAX United Kingdom
- Employees
- VERO N/A
- VRAX N/A
- Industry
- VERO Medical/Dental Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VERO Health Care
- VRAX Health Care
- Exchange
- VERO Nasdaq
- VRAX Nasdaq
- Market Cap
- VERO 4.6M
- VRAX 4.7M
- IPO Year
- VERO N/A
- VRAX 2022
- Fundamental
- Price
- VERO $2.19
- VRAX $0.81
- Analyst Decision
- VERO
- VRAX Strong Buy
- Analyst Count
- VERO 0
- VRAX 1
- Target Price
- VERO N/A
- VRAX $3.00
- AVG Volume (30 Days)
- VERO 3.3M
- VRAX 37.2K
- Earning Date
- VERO 08-12-2025
- VRAX 02-05-2025
- Dividend Yield
- VERO N/A
- VRAX N/A
- EPS Growth
- VERO N/A
- VRAX N/A
- EPS
- VERO N/A
- VRAX N/A
- Revenue
- VERO $60,997,000.00
- VRAX $84,872.00
- Revenue This Year
- VERO N/A
- VRAX $5,169.18
- Revenue Next Year
- VERO $7.47
- VRAX $66.97
- P/E Ratio
- VERO N/A
- VRAX N/A
- Revenue Growth
- VERO N/A
- VRAX 7.03
- 52 Week Low
- VERO $2.10
- VRAX $0.75
- 52 Week High
- VERO $14.50
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- VERO 41.93
- VRAX 31.75
- Support Level
- VERO $2.15
- VRAX $0.75
- Resistance Level
- VERO $4.25
- VRAX $0.85
- Average True Range (ATR)
- VERO 0.33
- VRAX 0.07
- MACD
- VERO -0.03
- VRAX -0.01
- Stochastic Oscillator
- VERO 2.38
- VRAX 6.57
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.